HUE064449T2 - Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra - Google Patents

Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra

Info

Publication number
HUE064449T2
HUE064449T2 HUE15818148A HUE15818148A HUE064449T2 HU E064449 T2 HUE064449 T2 HU E064449T2 HU E15818148 A HUE15818148 A HU E15818148A HU E15818148 A HUE15818148 A HU E15818148A HU E064449 T2 HUE064449 T2 HU E064449T2
Authority
HU
Hungary
Prior art keywords
hepatitis
phosphorotiotated
chelated
treatment
nucleic acid
Prior art date
Application number
HUE15818148A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064449(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of HUE064449T2 publication Critical patent/HUE064449T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HUE15818148A 2014-07-10 2015-07-07 Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra HUE064449T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15

Publications (1)

Publication Number Publication Date
HUE064449T2 true HUE064449T2 (hu) 2024-03-28

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15818148A HUE064449T2 (hu) 2014-07-10 2015-07-07 Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra

Country Status (33)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR102734495B1 (enExample)
CN (2) CN113750112A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113651853A (zh) * 2020-05-07 2021-11-16 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦c晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
NZ606364A (en) 2010-08-20 2014-12-24 Replicor Inc Oligonucleotide chelate complexes
DK2632472T3 (en) * 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
IN2015DN01087A (enExample) * 2012-08-30 2015-06-26 Replicor Inc

Also Published As

Publication number Publication date
EP3166615B1 (en) 2023-08-09
MX2017000053A (es) 2017-05-01
FI3166615T3 (fi) 2023-11-06
AU2015286199B2 (en) 2020-05-14
PT3166615T (pt) 2023-11-13
IL249660B (en) 2022-02-01
IL249660A0 (en) 2017-02-28
RS64833B1 (sr) 2023-12-29
ECSP16097355A (es) 2017-03-31
JP2017521433A (ja) 2017-08-03
CA2954182C (en) 2023-08-15
CL2017000008A1 (es) 2017-06-09
MY178087A (en) 2020-10-02
CN106659730A (zh) 2017-05-10
DK3166615T3 (da) 2023-11-13
LT3166615T (lt) 2024-01-25
CA2954182A1 (en) 2016-01-14
PH12017500010A1 (en) 2017-05-15
EP3166615A1 (en) 2017-05-17
PH12017500010B1 (en) 2022-07-29
DOP2017000002A (es) 2017-03-15
KR20170029577A (ko) 2017-03-15
JP2020143065A (ja) 2020-09-10
TWI766831B (zh) 2022-06-11
JP6922030B2 (ja) 2021-08-18
MD4760B1 (ro) 2021-07-31
US9603865B2 (en) 2017-03-28
EA201790160A1 (ru) 2017-06-30
EP3166615A4 (en) 2018-01-17
WO2016004525A1 (en) 2016-01-14
MD20170014A2 (ro) 2017-07-31
BR112017000320B1 (pt) 2023-02-07
HK1231402A1 (zh) 2017-12-22
KR102734495B1 (ko) 2024-11-25
BR112017000320A2 (pt) 2017-11-07
MD4760C8 (ro) 2022-02-28
US20160008393A1 (en) 2016-01-14
NZ727583A (en) 2024-08-30
HRP20231400T1 (hr) 2024-02-16
CN113750112A (zh) 2021-12-07
PL3166615T3 (pl) 2024-02-19
AU2015286199A1 (en) 2017-02-23
SI3166615T1 (sl) 2023-12-29
SG11201700073PA (en) 2017-02-27
SMT202300380T1 (it) 2024-01-10
ES2963814T3 (es) 2024-04-02
KR20230070330A (ko) 2023-05-22
EA036745B1 (ru) 2020-12-16
MX381042B (es) 2025-03-12
CU20170001A7 (es) 2017-04-05
TW201613617A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
HUE064449T2 (hu) Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
IL265921A (en) Transgenic meganonucleases specific for recognition sequences in the hepatitis b virus genome
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
DK3546585T3 (da) Nukleinsyrer med en modificeret intron til brug i behandlingen af hyperbilirubinæmi
ZA201701643B (en) Pyrrolopyrimidines for use in influenza virus infection
IL237173A0 (en) Methods for treating hepatitis b and hepatitis d infections
IL254243B (en) Hepatitis C virus polymerase inhibitors.
HUE044606T2 (hu) A hepatitis delta vírusfertõzés kezelése
IL255366A0 (en) Reagents for the treatment of hepatitis B infection and their use
PL3463469T3 (pl) Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi
WO2014160088A3 (en) Treating hepatitis b virus infections
EP3271371A4 (en) Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
TH1601002531A (th) กรดนิวคลีอิกและวิธีการสำหรับการตรวจหาเชื้อก่อโรคและจุลินทรีย์ที่เป็นประโยชน์
AU2015901617A0 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof